高级检索
    董晓荣, 王千毓. 纳武利尤单抗联合伊匹木单抗一线治疗非小细胞肺癌的疗效[J]. 循证医学, 2020, 20(1): 43-48. DOI: 10.12019/j.issn.1671-5144.2020.01.010
    引用本文: 董晓荣, 王千毓. 纳武利尤单抗联合伊匹木单抗一线治疗非小细胞肺癌的疗效[J]. 循证医学, 2020, 20(1): 43-48. DOI: 10.12019/j.issn.1671-5144.2020.01.010
    shu
    DONG Xiao-rong, WANG Qian-yu. Efficacy of Nivolumab plus Ipilimumab as First-Line Treatment in Non-Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2020, 20(1): 43-48. DOI: 10.12019/j.issn.1671-5144.2020.01.010
    Citation: DONG Xiao-rong, WANG Qian-yu. Efficacy of Nivolumab plus Ipilimumab as First-Line Treatment in Non-Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2020, 20(1): 43-48. DOI: 10.12019/j.issn.1671-5144.2020.01.010
    shu

    纳武利尤单抗联合伊匹木单抗一线治疗非小细胞肺癌的疗效

    Efficacy of Nivolumab plus Ipilimumab as First-Line Treatment in Non-Small-Cell Lung Cancer

      摘要
      • HTML全文
      • 参考文献(21)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回